|
Treatments |
||||
| Clozapine N = 6 |
Risperidone N = 20 |
Olanzapine N = 31 |
Quetiapine N = 19 |
|
|
|
||||
| SGA Medication |
||||
| Dose (mg) |
441.3 ± 142.9 |
2.7 ± 1.6 |
10.4 ± 5.8 |
330.3 ± 300.9 |
| Duration (months) |
12.7 ± 12.4 |
12.8 ± 10.7 |
9.8 ± 11.5 |
7.4 ± 3.9 |
| Other treatments with metabolic side effects1 |
3 (50%) |
3 (16%) |
7 (23%) |
5 (26%) |
| Previous treatment |
||||
| Naive* |
0 |
10 (50%) |
13 (42%) |
2 (10%) |
| SGA** |
3 (3%) |
3(15%) |
6(19%) |
11 (58%) |
| FGA |
3 (11%) |
7 (35%) |
12 (39%) |
6 (32%) |
|
1Other treatments with metabolic side effects were first generation antipsychotics, carbamazepine, lithium, sodium valproate, mirtazapine. *chi-sq 11.7, df 3, p = 0.009 ** chi-sq 11.5, df 3, p = 0.009 | ||||
Tarricone et al. BMC Psychiatry 2006 6:11 doi:10.1186/1471-244X-6-11 |
||||